Suchergebnisse - "De Giorgi, Ugo"

PubPharm (40)

21

Darolutamide in hormone-sensitive and castration-resistant prostate cancer

enthalten in: Expert review of clinical pharmacology | 2021

von Palmieri, V. | Roviello, G. | D'Angelo, A. | +3

22

Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer

enthalten in: Expert opinion on pharmacotherapy | 2020

von Altavilla, A. | Casadei, C. | Lolli, C. | +12

23

Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer : An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study

enthalten in: European urology | 2020

von Stenzl, A. | Dunshee, C. | De Giorgi, U. | +10

24

Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer

enthalten in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | 2020

von Banna, G. | Urzia, V. | Benanti, C. | +10

25

Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy

enthalten in: Journal of clinical medicine | 2020

von Conteduca, V. | Caffo, O. | Scarpi, E. | +19

26

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

enthalten in: The New England journal of medicine | 2020

von Sternberg, C. | Fizazi, K. | Saad, F. | +116

CommentIn: Cancer Cell. 2020 Jul 13;38(1):25-27. - PMID 32663466

27

Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer : An International Collaborative Analysis

enthalten in: European urology oncology | 2020

von Rescigno, P. | Dolling, D. | Conteduca, V. | +24

28

Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer

enthalten in: Clinical genitourinary cancer | 2020

von Caffo, O. | Wissing, M. | Bianchini, D. | +16

ErratumIn: Clin Genitourin Cancer. 2020 Apr 19;:. - PMID 32321674

29

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide

enthalten in: Frontiers in oncology | 2020

von Gurioli, G. | Conteduca, V. | Lolli, C. | +6

30

Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide

enthalten in: The Prostate | 2019

von Lolli, C. | De Lisi, D. | Conteduca, V. | +11